Biotech market spotlight: Blackmores

By Tim Dean
Friday, 30 October, 2009

Natural vitamin and supplement company, Blackmores (ASX:BKL) has enjoyed another strong year of revenue and profit growths despite the global financial wobbles and a strengthening Australian dollar.

In an announcement made to its shareholders recently, it revealed revenues for the last financial year were up 12 per cent to $200 million, and after tax profits were up 9% to $20.8 million.

The first quarter of this financial year saw revenues go up by 17 per cent, although after tax profits fell by 4.1 per cent to $6.9 million.

Growth in Asia has been strong over the past financial year, aided by concerns over swine flu. Sales in Asia grew by 37 per cent in FY2009 compared to 14 per cent in Australia and 7 per cent in New Zealand.

Blackmores also launched seven new products, including a range targeted at children and a new Heart Health range this quarter, and has more products it aims to release this financial year.

Blackmores was up 7 per cent, or $1.45, to $22.15 in today's trading, which is only 55c shy of an 18 month high.

Related News

Novel antibiotic activates 'suicide' mechanism in superbug

Researchers have discovered a new class of antibiotic that selectively targets Neisseria...

Modifications in the placenta linked to psychiatric disorders

Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...

ADHD may be linked with an increased risk of dementia

An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd